Moore M P, Ihde J K, Crowe J P, Hakes T P, Kinne D W
Memorial Sloan Kettering Cancer Center, New York, NY 10021.
Arch Surg. 1991 Mar;126(3):304-6. doi: 10.1001/archsurg.1991.01410270044008.
Historically, the prognosis of inflammatory breast cancer has been poor. We conducted a retrospective review to evaluate the recent Memorial Sloan-Kettering Cancer Center experience, to evaluate the role of combination chemotherapy, and to compare the effect of surgery and radiation on local/regional failure. Fifty-six patients with local/regional inflammatory breast cancer diagnosed between 1975 and 1984 were identified. All were treated with combination chemotherapy. Overall 5-year survival was 45% with a 5-year disease-free survival rate of 37%. Twenty-one patients were treated with induction chemotherapy followed by mastectomy and adjuvant chemotherapy. Survival and disease-free survival rates were similar to those achieved in patients treated with mastectomy followed by chemotherapy. Residual cancer was found in all 21 patients treated with induction chemotherapy, with extensive disease present in 18, including six of seven complete responders. The local/regional failure rate was 34%.
从历史上看，炎性乳腺癌的预后一直很差。我们进行了一项回顾性研究，以评估纪念斯隆凯特琳癌症中心近期的经验，评估联合化疗的作用，并比较手术和放疗对局部/区域复发的影响。确定了1975年至1984年间诊断为局部/区域炎性乳腺癌的56例患者。所有患者均接受联合化疗。总体5年生存率为45%，5年无病生存率为37%。21例患者接受诱导化疗，随后进行乳房切除术和辅助化疗。生存率和无病生存率与先进行乳房切除术然后化疗的患者相似。在所有21例接受诱导化疗的患者中均发现有残留癌，其中18例存在广泛病变，包括7例完全缓解者中的6例。局部/区域复发率为34%。
